SDWG Clinical Oncology Treatment Plan CDA IG Ballot development meetings

PurposeTeam Weekly Conference Call

DateFebruary 26, 2013

Time 5:30 pm – 6:30 pm EST

Agenda

1. New Introductions 5 minutes
2. This week’s sections 50 minutes
   * Medication Section
   * Results Section
3. Wrap Up/Conclusion 5 minutes

Attendees

* **Jeff Kan, Suzanne Maddux** from ASCO
* **Gaye Dolin, Zabrina Gonzaga**, **Yan Heras,** **Beau Bannerman** from Lantana
* **Mark Shafarman** – Interested party, HL7 member
* **John Krauss**
* **Dr. Warner**

Meeting Minutes

Medication Section BCTPS and entries

* Chemotherapy Regimen – like a wrapper.

Propose in <originalText> put Chemotherapy name.

* + **Chemotherapy Medication Activity**

Reviewed effective time next week.

Not restricted to agents right now.

Outstanding question: Should we have a valueSet for Chemotherapy agents?

Response: Leave unrestricted.

* + **Clinical Drug Trial**
    - Action: Add a conformance statement.

Represents if treatment is part of a clinical trial.

* + **Drug Therapy Discontinued**
    - Add “Progression” to table.
    - Add “ASCO QOPI”.
    - QOPI- Jeff will send list to us.

Q: What if vendors don’t use these SNOMED CT codes?

A: Hopefully would map so they align with codes in the valueSet.

* + ValueSet Reason for therapy discontinue
    - Free text or valueSet?
  + **Possible Side Effects**

Communicate the common side effects.

Add to ValueSet Chemotherapy Side Effects –

Low WBC

Low platelet count

Cardiotoxicity (important)

Loss of fertility

Infection

* + Update template: Allow for OTHER. Make it clear in template.
  + Update template: Make 1..\* (CONF 24033)
  + Research: Some capture side effects using CTCAE Structured Criteria (big data set, scope?).

Think about for future:

LINKS:

<http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm>

**pdf link:**

<http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf>

**Note: check VSAC or phinvads to see valueSets are in there.**

**CTCAE v. 4.0 in Excel:** <http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14.xls>

* + **Therapy Side Effects**
    - Optional. Represent in Allergy/Adverse event Section? In Allergy/Adverse event section can reference a problem, observation, procedure.
    - Side effects that actually occurred.

Comment: When known, life threatening adverse event – in this section. Therapy Side effect is expected event and would not preclude them from getting the chemo in the future. “Need to call out - Dangerous side effects from a drug”.

* + - Leave it as is. Keep it in here. CTCAE grading schema is correlated to this. Grading I and II not as serious. III and above are more serious.
* **A****nthracycline Medication Activit****y**
  + Anthracycline Medication Information
  + Could this be represented as part of the Chemotherapy Regimen?
    - Pulled out b/c of the cardiotoxicity.
    - Also there could be a curative regimen.
    - Information is hard to retrieve.
    - Anthracycline is a class of drugs.
      * Doxyrubicin and Epirubicin are common ones used adjuvant treatment. Add theses and keep the valueSet (DYNAMIC).
        + Q: then for Doxyrubicin need to represent “If yes, how much?” Is this represented?
        + R: Represented in the Chemotherapy regimen.
    - Want to call this out and not constraining medications in the Chemotherapy Regimen. Create a template outside that is simple substance administration template that would not conform to medication activity but assert that they received this class of Drug. Then the details are represented in the chemotherapy regimen and keeps details in Chemotherapy regimen.
    - Jeff will follow up to see if there is a Quality Measures that uses this?
    - Will revisit this with effective timing.

Action ITEMS

Follow up with Suzanne on scheduling a meeting to review the Ballot Process with ASCO Stake holders.

Next Week

Finish up Medications Section BCTPS and follow up on Anthracycline template

Review updates to Results Section BCTPS

Review updates on ValueSets